Strategy for Viral Safety Risk Reassessment with Changes in the Manufacturing Process of Recombinant Biotechnology Products

Engineering

Paper Video Conference Expert

Subscribe Submit

2024, Volume 32, Issue 1

Related Research

Back to Top

Strategy for Viral Safety Risk Reassessment with Changes in the Manufacturing Process of Recombinant Biotechnology Products

Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China

Received: 2023-07-10 Revised: 2023-09-28 Accepted: 2023-10-07 Available online: 2023-11-25

HTML3 PDF 23 Collect 0

Next Previous

Related Research

关注我们